Overview
- TrumpRx will offer starter injections of Wegovy and Zepbound at about $350 per month beginning in January, trending toward roughly $245 over two years, with oral starters expected around $149 once approved.
- Medicare will begin a pilot by mid-2026 covering eligible seniors at about $245 per month with a $50 copay, limited to patients meeting BMI and specific comorbidity criteria that officials estimate include roughly 10% of beneficiaries.
- States can opt in for Medicaid coverage at the $245 monthly price, while implications for private insurer coverage were not detailed.
- The agreements include most-favored-nation pricing commitments and relief from threatened tariffs, with officials also pointing to regulatory incentives for the manufacturers.
- List prices for GLP-1 drugs commonly exceed $1,000 per month today, and while the White House projects health gains from expanded access, analysts note unanswered questions about program costs, insurer behavior and supply.